Application of epothilones in breast cancer therapy

Current Opinion in Oncology

Volumn 20, Issue 6, 2008, Pages 634-638

  Cianfrocca, Mary ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Epothilones; Metastatic breast cancer; Taxanes

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; EPOTHILONE A; EPOTHILONE B; IXABEPILONE; PACLITAXEL;

ALOPECIA; ASTHENIA; BREAST CANCER; CANCER THERAPY; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; METASTASIS; MOTOR NEUROPATHY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; UNITED STATES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; MICROTUBULES; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 55749112323     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32831270b0     Document Type: Review

References (16)

1. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981; 91:479-487.
2. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins, and guanine nucleotides in tubulin polymerization. J Biol Chem 1981; 20:3247-3252.
3. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-2333.
4. Kowalski RJ, Giannakakous P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997; 272:2534-2541.
5. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on a, β-tubulin by electron crystallography. Science 2004; 305:866-869.
6. Bode CJ, Qupta ML, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41:3870-3874.
7. Lee FYF, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but posessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-1437.
8. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21:1866-1873.
9. Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone alnalog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007; 25:1082-1088.
10. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-2734.
11. Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2006; 25:63-67.
12. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25:3421-3427.
13. Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothitone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25:3415-3420.
14. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone, an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-3406. This trial demonstrated the efficacy of single-agent ixabepilone in patients with taxane-resistant MBC.
15. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550), in a phase II study of patients with advanced breast cancer résistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 2007; 25:3407-3414. Registration trial leading to FDA approval of single-agent ixabepilone in patients with anthracycline-resistant, taxane-resistant and capecitabine-resistant MBC.
16. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-5217. Registration trial leading to FDA approval of the combination of ixabepilone and capecitabine in patients with anthracycline-resistant and taxane-resistant MBC.